Jacobs Levy Equity Management, Inc C4 Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 441,735 shares of CCCC stock, worth $980,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
441,735
Previous 697,653
36.68%
Holding current value
$980,651
Previous $1.12 Million
43.46%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CCCC
# of Institutions
105Shares Held
57.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$16.5 Million0.06% of portfolio
-
Lynx1 Capital Management LP San Juan, PR7.1MShares$15.8 Million3.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.5 Million0.77% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$15.2 Million0.35% of portfolio
-
Morgan Stanley New York, NY4.75MShares$10.6 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $109M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...